Kornimate/medical-research-clean huggingface dataset:
tongue diagnosis in chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: the automatic tongue diagnosis system (atds) was developed to capture tongue images and extract features reliably to assist the diagnosis of traditional chinese medicine (tcm) practitioners.this project will employ the atds verified to extract the tongue features of patients with chronic kidney disease. a tcm indices derived through the non-intrusive tongue diagnosis procedure can provide valuable information for clinical doctors to analyze the current status of a patient and dynamically schedule a treatment plan, facilitating early detection and diagnosis of chronic kidney disease.

chronic kidney disease (ckd) is a global financial and medical burden, because its high morbidity and mortality. tongue diagnosis is an important diagnostic tool in traditional chinese medicine. however, tongue diagnosis often biased by subjective judgements and environmental factors. the automatic tongue diagnosis system can noninvasively capture tongue images, automatically correct any lighting and color deviation and analyze tongue manifestations. this protocol is a cross-sectional, case-controlled observational study investigating the tongue features of non-dialysis ckd and end-stage renal disease patients by using the noninvasive atds. ckd patients who meets inclusion and exclusion criteria will be enrolled. participants will be divided into 3 groups according to their renal function and accept dialysis or not, including a non-dialysis ckd group, end stage renal disease (esrd) group and control group. tongue images will be captured and 9 tongue features including tongue shape, tongue color, fur thickness, fur color, saliva, tongue fissure, ecchymosis, tooth mark, and red dots will be extracted and analyzed by atds. this protocol aims to apply noninvasive atds to analyze tongue features of ckd patients.

Eligibility criteria:
inclusion criteria: the patients will be included if they meet the following criteria: 1. age over 20 years old 2. the person who volunteered to participate this research and signed the agreement of institutional review board. exclusion criteria: 1. pregnant women 2. patients with acute infection 3. the person who has cancer with brain metastasis and present with cognitive dysfunction such as dementia or delirium 4. unable to protrude the tongue stably 5. patients with risk of temporomandibular joint dislocation 6. those who did not sign the agreement of institutional review board

Keywords: chronic kidney diseases automatic tongue diagnosis system traditional chinese medicine
registry of pediatric patients diagnosed with crohn's disease in belgium

Conditions: Description of Disease Course, Disease Fenotype, Medication, Safety, Analysis for Possible Associations

Summary: a registry of pediatric patients (under 18 yrs of age) diagnosed with crohn's disease was created in belgium. over a 2 year period 257 patients are included. these patients will be follow up prospectively during 5 years. demographic data, family history, disease presentation and disease course including medication are registered in crf's.


Eligibility criteria:
inclusion criteria: 1-18 yrs old belgian crohn s disease informed consent exclusion criteria: no informed consent

Keywords: pediatrics, crohn's disease, disease course, therapy
interventions to promote healthy eating and physical activity in lebanese school children targeting overweight and obesity- pilot study

Conditions: Childhood Obesity

Summary: evaluate the feasibility and effectiveness of a multi-component school-based intervention to promote healthy eating and physical activity with school children ages 9 to 11 years in lebanon.


Eligibility criteria:
inclusion criteria: * schoolchildren * aged 9 to 11 years exclusion criteria: - no exclusion criteria

Keywords: school-based intervention
promoting self-management behaviors in adolescents with type 1 diabetes, using digital storytelling

Conditions: Diabetes Mellitus, Type 1; Self-Management

Summary: the aim of this study was to evaluate the effects of digital storytelling on the self-management behavior of adolescents with type 1 diabetes (tid).

in this single-blind randomized controlled trial, 60 eligible adolescents with tid were selected based on a convenient sampling method. next, the participants were randomly allocated into two parallel groups: intervention (training with digital storytelling method, n=30) or control (training with conventional) n=30) groups. before and three months after the intervention the patients' levels of self-management behaviors according to self-management of tid amongst adolescents (smod-a); in addition to the glycated hemoglobin test (hba1c) were measured.

Eligibility criteria:
inclusion criteria: * adolescents with tid * using medication (insulin) * willing to participate in the study and complete the informed consent * having a basic knowledge of working with computers * ability to communicate on the telephone. exclusion criteria: * physical or mental disabilities * take anti-anxiety or antidepressant medication
concurrent nab-p/carboplatin and thoracic radiotherapy in squamous cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma

Summary: nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer. this study is conducted to evaluate the efficacy and safety of nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local advanced inoperable squamous cell lung cancer.

this study was conducted to explore the efficacy and safety of concurrent concurrent nab-paclitaxel, carboplatin and thoracic radiotherapy in inoperable local advanced squamous cell lung cancer. patients will be given nab-paclitaxel weekly at a dose of 40mg/m2, in combination with carboplatin (auc 2) weekly during concurrent chemoradiotherapy. thoracic radiation was administered at a dose of 60-66 gy/30-33 fractions, both 3 dimensional conformal and intensity modulated radiation therapy are allowed.

Eligibility criteria:
inclusion criteria: * age: 18 years to 70 years * performance status of 0 to 1 on the eastern cooperative oncology group (ecog) scale. * previously untreated, histological documented, inoperable stage iii squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes. * patients must have measurable disease according to recist criteria, and all detectable tumor can be encompassed by radiation therapy fields. * patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. * female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. * patients must sign a study-specific informed consent form prior to study entry. exclusion criteria: * complete tumor resection, recurrent disease, or those patients eligible for definitive surgery. * previous chemotherapy or previous biologic response modifiers for current lung cancer. * patient has previously had thoracic radiation therapy. * prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more. * serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator. * history of significant neurological or mental disorder, including seizures or dementia.
clinical diagnosis of acute appendicitis with normal wbcs count with role of inflammatory markers and radiology

Conditions: Acute Appendicitis

Summary: the aim of this study is to describe the proportion of pa-tients with normal preoperative inflammatorymarkers among patients with histopathologically proven acute appendicitis

2.4.1- type of the study: prospective clinical trial study 2.4. 2- study setting: assuit university hospital 2.4. 3- study subjects: 1. inclusion criteria: patients complain of rt iliac pain with us positive for acute appendicitis with wbcs normal . 2. exclusion criteria: malignant mass cancer appendix mesenteric adentis cecal diverticulum salpingitis c. sample size calculation: 50 cases 2.4.4 -study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): lab wbcs count crp level neutrophil differential count clinical correlation us findings and msct if needed

Eligibility criteria:
inclusion * male or female patients é clinically diagnosed acute appendicitis with normal wbcs exclusion criteria: * complicated aa (perforation, peri appendicular abscess or suspicion of a tumor. 2_inflammatory bowel diseases 3_inability to co-operate and give informed consent 4_diffuse peritonitis 5_patients with serious comorbid conditions dm \& renal insufficiency, serum creatinine \> 150 μmol/l 6_pregnant \& lactating patient 7_patients with advanced malignancies \& pt on immunosuppressive drugs

Keywords: clinical diagnosis of acute appendicitis
a study to assess the safety, pharmacokinetics, and efficacy of intravenous (iv) abbv-303, as monotherapy and in combination with iv infused budigalimab (abbv-181), in adults with advanced solid tumors

Conditions: Solid Tumors

Summary: cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. the purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of abbv-303 as a monotherapy and in combination with budigalimab, (abbv-181). abbv-303 is an investigational drug being developed for the treatment of solid tumors. there are multiple treatment arms in this study. participants will either receive abbv-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. approximately 181 adult participants will be enrolled in the study across sites worldwide. in part a, abbv-303 will be intravenously (iv) infused in escalating doses as a monotherapy in participants with relapsed (r)/refractory (r) solid tumors, r/r non-small cell lung cancer (nsclc), r/r renal cell carcinoma (rcc), r/r head and neck squamous cell carcinoma (hnscc), or r/r tissue agnostic participants with mesenchymal epithelial transition. in part b, abbv-303 in combination with budigalimab will be iv infused in participants with r/r solid tumors or nsclc. the estimated duration of the study is up to 3 years. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.


Eligibility criteria:
inclusion criteria: * participants with eastern cooperative oncology group (ecog) performance status of 0 or 1. * laboratory values meeting the protocol's criteria within the screening period (-28 days) prior to the first dose of study drug. * participants with a diagnosis of a malignant solid tumor by histology (world health organization \[who\] criteria). * participants with measurable disease per response evaluation criteria in solid tumors version 1.1 (recist v1.1). exclusion criteria: * unresolved grade \> 1 adverse events (aes) from prior anti-cancer therapy except for alopecia. * active systemic or uncontrolled local bacterial, fungal, or viral infection requiring antimicrobial therapy. * history of hypersensitivity to the active ingredients or any excipients of abbv-303 and budigalimab (abbv-181). * body weight \< 35 kg.

Keywords: solid tumors non-small cell lung cancer nsclc renal cell carcinoma rcc head and neck squamous cell carcinoma hnscc abbv-303 abbv-181 budigalimab
myosure hysteroscopic tissue removal system registry study

Conditions: Uterine Fibroids; Polyps

Summary: the objective of this study is to demonstrate the safety and effectiveness of community gynecologist initiated treatment of intra-uterine polyps and submucosal fibroids with the myosure hysteroscopic tissue removal system in a significantly sized patient population.

between 500 and 600 subjects will be enrolled in a prospective, multi-center registry study. approximately 100 of these cases will be completed in an office setting, with the remaining 400-500 cases completed in a hospital outpatient or ambulatory surgery center. subjects will undergo a hysteroscopic tissue removal procedure to remove intrauterine polyps and submucosal fibroids.

Eligibility criteria:
inclusion criteria: 1. healthy female between 18 and 65 years of age 2. subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her 3. subject is indicated for myomectomy or polypectomy 4. subject exhibits intrauterine polyps and/or submucous myomas which meet one of the following criteria. in cases of subjects with multiple intrauterine pathology, classification is based as follows: * all polyps * all type 0, type 1 or type 2 myomas ≤ 6 cm in diameter * polyps plus type 0, type 1 or type 2 myomas ≤6 cm in diameter exclusion criteria: 1. subject is pregnant 2. subject has an intrauterine device (iud) at the time of the procedure. a subject may be enrolled in the study if the iud is removed prior to the treatment procedure 3. subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin 4. active pelvic inflammatory disease or pelvic/vaginal infection 5. subject has a known or suspected coagulopathy or bleeding disorder 6. subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction) 7. subject has other co-morbid condition(s) that, in the opinion of the investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study

Keywords: morcellator hysteroscope myomectomy polypectomy uterine fibroids uterine polyps
a safety and efficacy study of r935788 in the treatment of warm antibody autoimmune hemolytic anemia (aiha)

Conditions: Warm Antibody Autoimmune Hemolytic Anemia

Summary: the purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of warm antibody autoimmune hemolytic anemia (aiha).


Eligibility criteria:
inclusion criteria: subject must have had a diagnosis of primary or secondary warm antibody aiha. - must have failed at least 1 prior treatment regimen for aiha. exclusion criteria: * subject with cold antibody aiha, cold agglutinin syndrome, mixed type aiha, or paroxysmal cold hemoglobinuria. * subject with a platelet count of \< 30,000/μl. * subject has aiha secondary to autoimmune disease, including systemic lupus erythematosis (sle), or lymphoid malignancy and the underlying disease is not stable or is not well-controlled on current therapy. * subject has uncontrolled or poorly controlled hypertension, defined as systolic blood pressure ≥ 130 mmhg, or diastolic blood pressure ≥ 80 mmhg.

Keywords: warm antibody autoimmune hemolytic anemia (aiha)
turkish version of the ankle instability instrument

Conditions: Ankle Injuries

Summary: this study aimed to translate the ankle instability instrument into turkish language, to perform a cultural adaptation study and to evaluate its validity and reliability in the turkish population. ankle instability instrument was developed to determine the ankle instability level of individuals with a history of ankle injury. assessment of ankle instability is particularly useful in determining the complaints and functional levels of individuals with a history of functional or chronic ankle instability. it is anticipated that introducing this scale to our language will contribute to other studies in this field.


Eligibility criteria:
inclusion criteria: * history of ankle injury or sprain at least one time * aged between 18 to 40 years exclusion criteria: * neurological or orthopedic disorders that may affect ankle instability. inclusion criteria for healthy population are; no history of ankle injury or sprain before and. aged between 18 to 40 years
long-term follow-up of patients undergoing catheter ablation

Conditions: Arrhythmia

Summary: the purpose of this study is to assess the long-term effects of catheter ablation procedures performed at the ou medical center.

the purpose of this study is to assess the long-term effects of catheter ablation procedures performed at this institution, including recurrence of the ablated arrhythmia and any late complications.

Eligibility criteria:
inclusion criteria: * undergoing catheter ablation at the ou medical center exclusion criteria: * prisoners * refusal to participate

Keywords: arrhythmia catheter ablation
clinical comparison of two daily disposable silicone hydrogel soft contact lens

Conditions: Myopia

Summary: the objective of this study is to evaluate a new daily disposable silicone hydrogel soft contact lens by comparing to an existing daily disposable soft contact lens.

this study is designed to evaluate the performance of the olifilcon b contact lens to demonstrate substantial equivalence to the narafilcon a for regulatory requirement.

Eligibility criteria:
inclusion criteria: * subject should have normal eyes and use no ocular medications * subject with -1.00 to -10.00 d myopia, less than 2.00 d astigmatism * va correctable to log mar 0.1 or better. * willing to comply with all study procedures and be available for the duration of the study. * provide signed and dated informed consent form. exclusion criteria: * subjects have history of allergies that would contraindicate "normal" contact lens wear. * subjects have other active ocular or systemic disease such as, but not limited to : anterior uveitis (past or present), glaucoma, sjögren's syndrome, lupus erythematosus, sclerodermas, keratoconus or type ii diabetes. * subjects have medications that would contraindicate contact lens wear. * currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next 3 month. * current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * any active participation in another clinical trial within 30 days prior to this study. * the presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. * a known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections. * a history of papillary conjunctivitis that has interfered with contact lens wear.

Keywords: silicone hydrogel daily disposable soft contact lens
combination chemotherapy plus radiation therapy in treating patients with small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. it is not yet known which treatment regimen is more effective for small cell lung cancer. purpose: randomized phase iii trial to study the effectiveness of combination chemotherapy using two different doses of cyclophosphamide followed by alternating chemotherapy and radiation therapy in treating patients with small cell lung cancer.

objectives: i. compare the effect on 2-year disease-free survival of two different doses of cyclophosphamide as part of first induction chemotherapy followed by alternating chemotherapy and chest irradiation in patients with limited stage small cell lung cancer. outline: this is a randomized study. patients are stratified by participating institution. all patients receive 2 courses of induction chemotherapy with doxorubicin, etoposide, cisplatin, and cyclophosphamide. for the first course, one group of patients receives a lower dose of cyclophosphamide than the other group. both groups receive the same, and still lower, dose of cyclophosphamide during the second course. beginning 1 week after the completion of induction therapy, patients receive 3 alternating courses each of radiotherapy to the mediastinal and supraclavicular areas delivered over 10-12 days and chemotherapy as in the second course of induction. each course is initiated after a 1-week rest. patients receive a final chemotherapy course beginning 4 weeks after the previous chemotherapy course. patients are followed every 6 months for survival. projected accrual: a total of 280 patients will be entered.

Eligibility criteria:
disease characteristics: histologically proven small cell lung cancer with no distant metastases size of initial lesion suitable for total irradiation positive subclavicular nodes allowed no malignant pleural effusion no extension into contralateral lung patient characteristics: age: under 70 performance status: karnofsky 60%-100% hematopoietic: wbc greater than 2,000 platelets greater than 125,000 hepatic: not specified renal: creatinine less than 1.1 mg/dl (100 micromoles/l) cardiovascular: no myocardial infarction within 6 months no other cardiovascular disease that precludes protocol treatment other: no hearing loss no prior or concurrent malignancy except: basal cell skin carcinoma in situ carcinoma of the cervix accessible for follow-up prior concurrent therapy: no prior chemotherapy, radiotherapy, or surgery

Keywords: limited stage small cell lung cancer
a study of naltrexone sr/ bupropion sr in overweight or obese subjects with major depression

Conditions: Depression

Summary: the purpose of this study is to determine whether a combination of naltrexone sr and bupropion sr is safe and effective in the treatment of major depression in overweight or obese subjects.


Eligibility criteria:
inclusion criteria: * female and male subjects must be 18 to 65 years of age; * have body mass index (bmi) greater or equal to 27 and less than or to equal 43kg/m2; * meet criteria for major depression * women of child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug; * able to comply with all required study procedures and schedule; * able to speak and read english; * willing and able to give written informed consent exclusion criteria: * obesity of known endocrine origin * serious medical condition * history of drug or alcohol abuse or dependence * use of excluded concomitant medications * history of surgical or device (e.g. gastric banding) intervention for obesity; * history or predisposition to seizures * pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug; * planned surgical procedure that can impact the conduct of the study; * use of investigational drug, device or procedure within 30 days prior to screening; * participation in any previous clinical trial conducted by orexigen therapeutics; * any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.

Keywords: depression depressed overweight obese